Prolocor, a Philadelphia, PA-based healthcare startup, raised $5.2M in seed and grant funding.
The round was led by Green Park & Golf Ventures, with participation from Labcorp and a group of angel investors.
Prolocor also announced the receipt of a $2 million Phase II grant from the Small Business Innovation Research (SBIR) program of the National Institutes of Health (NIH). Funds from this grant will be used to support the analytical validation of platelet expression of FcγRIIa as a precision tool.
Led by CEO Dr. DiBattiste, Prolocor is developing an innovative precision diagnostic test with the potential to predict the risk of thrombosis by quantifying FcγRIIa on the surface of platelets. The precision tool will guide treatment decisions, effectively matching the intensity of therapy with the risk of events.
FinSMEs
18/08/2022